FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:969-970 February 28, 2008 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Falutz, J. PubMed Citation

To the Editor: In their article on the effects of growth hormone–releasing factor in patients with human immunodeficiency virus (HIV) infection, Falutz and colleagues (Dec. 6 issue)¹ state that tesamorelin, a synthetic growth hormone–releasing factor, might be useful in the treatment of lipodystrophy related to antiretroviral drugs. However, the primary end point of the trial was the reduction of visceral adipose tissue as assessed by computed tomographic scanning; the study was not designed to detect a reduction in cardiovascular risk. These results came after the decision by the Food and Drug Administration (FDA) not to grant as an indication for . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.